EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

YBX1 promotes stemness and cisplatin insensitivity in intrahepatic cholangiocarcinoma via the AKT/ β ‐catenin axis

Xiaodong Shi, Zhiliang Hu, Shilei Bai, Chen Zong, Hui Xue, Yao Li, Fengwei Li, Liangrui Chen, Jianbing Xuan, Yong Xia, Lixin Wei, Feng Shen und 1 weitere

The Journal of Gene Medicine · 2024

DOI: 10.1002/jgm.3689 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Gene Medicine, 2024. Verfasst von Xiaodong Shi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatic Surgery II, the Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China. Hauptthemen laut MEDLINE: beta Catenin, Cholangiocarcinoma, Cisplatin, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Clinical Research Plan for SHDC, Explorer Program of Science and Technology Commission of Shanghai Municipality, Program of Science and Technology Commission of Shanghai Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Intrahepatic cholangiocarcinoma (ICC) is a highly aggressive malignancy characterized by a poor prognosis and closely linked to tumor stemness. However, the key molecules that regulate ICC stemness remain elusive. Although Y‐box binding protein 1 (YBX1) negatively affects prognosis in various cancers by enhancing stemness and chemoresistance, its effect on stemness and cisplatin sensitivity in ICC remains unclear.

Methods

Three bulk and single‐cell RNA‐seq datasets were analyzed to investigate YBX1 expression in ICC and its association with stemness. Clinical samples and colony/sphere formation assays validated the role of YBX1 in stemness and sensitivity to cisplatin. AZD5363 and KYA1979K explored the interaction of YBX1 with the phosphatidylinositol 3‐kinase (PI3K)/protein kinase B (PKB/AKT) and WNT/ β ‐catenin pathways.

Results

YBX1 was significantly upregulated in ICC, correlated with worse overall survival and shorter postoperative recurrence time, and was higher in chemotherapy‐non‐responsive ICC tissues. The YBX1‐high group exhibited significantly elevated stemness scores, and genes linked to YBX1 upregulation were enriched in multiple stemness‐related pathways. Moreover, YBX1 expression is significantly correlated with several stemness‐related genes ( SOX9 , OCT4 , CD133 , CD44 and EPCAM ). Additionally, YBX1 overexpression significantly enhanced the colony‐ and spheroid‐forming abilities of ICC cells, accelerated tumor growth in vivo and reduced their sensitivity to cisplatin. Conversely, the downregulation of YBX1 exerted the opposite effect. The transcriptomic analysis highlighted the link between YBX1 and the PI3K/AKT and WNT/ β ‐catenin pathways. Further, AZD5363 and KYA1979K were used to clarify that YBX1 promoted ICC stemness through the regulation of the AKT/ β ‐catenin axis.

Conclusions

YBX1 is upregulated in ICC and promotes stemness and cisplatin insensitivity via the AKT/ β ‐catenin axis. Our study describes a novel potential therapeutic target for improving ICC prognosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

beta CateninCholangiocarcinomaCisplatinDrug Resistance, NeoplasmGene Expression Regulation, NeoplasticY-Box-Binding Protein 1AnimalsFemaleHumansMaleMiceAntineoplastic AgentsBile Duct NeoplasmsCell Line, TumorCell ProliferationNeoplastic Stem CellsPrognosisProto-Oncogene Proteins c-aktWnt Signaling PathwayXenograft Model Antitumor Assays

Stichwörter der Autor:innen

YBX1chemoresistanceintrahepatic cholangiocarcinomastemness

Substanzen

Antineoplastic Agentsbeta CateninCisplatinProto-Oncogene Proteins c-aktY-Box-Binding Protein 1YBX1 protein, human

Autor:innen und Institutionen

  • Department of Hepatic Surgery II, the Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.
  • Department of Tumor Immunology and Gene Therapy Center, Third Affiliated Hospital of Naval Medical University, Shanghai, China.
  • National Center for Liver Cancer, Shanghai, China.
  • Department of Hepatic Surgery IV, the Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.

Förderung

  • Clinical Research Plan for SHDC
  • Explorer Program of Science and Technology Commission of Shanghai Municipality
  • Program of Science and Technology Commission of Shanghai Municipality
  • "Qianghai" Innovation Team Program of Naval Military Medical University

Zitieren

APA

Shi, X., Hu, Z., Bai, S., Zong, C., Xue, H., Li, Y., Li, F., Chen, L., Xuan, J., Xia, Y., Wei, L., Shen, F., & Wang, K. (2024). YBX1 promotes stemness and cisplatin insensitivity in intrahepatic cholangiocarcinoma via the AKT/ β ‐catenin axis. The Journal of Gene Medicine. https://doi.org/10.1002/jgm.3689

Vancouver

Shi X, Hu Z, Bai S, Zong C, Xue H, Li Y, et al. YBX1 promotes stemness and cisplatin insensitivity in intrahepatic cholangiocarcinoma via the AKT/ β ‐catenin axis. The Journal of Gene Medicine. 2024. doi:10.1002/jgm.3689

BibTeX
@article{Shi2024,
  author = {Shi, Xiaodong and Hu, Zhiliang and Bai, Shilei and Zong, Chen and Xue, Hui and Li, Yao and Li, Fengwei and Chen, Liangrui and Xuan, Jianbing and Xia, Yong and Wei, Lixin and Shen, Feng and Wang, Kui},
  title = {YBX1 promotes stemness and cisplatin insensitivity in intrahepatic cholangiocarcinoma via the AKT/ β ‐catenin axis},
  journal = {The Journal of Gene Medicine},
  year = {2024},
  doi = {10.1002/jgm.3689}
}
Kostenlos starten →